Journal article
Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma
Abstract
OBJECTIVES: Fluticasone furoate (FF; inhaled corticosteroid) combined with vilanterol (VI; long-acting beta(2) agonist) is a once-daily therapy for asthma and chronic obstructive pulmonary disease. This 12-week phase III study compared the efficacy and safety of once-daily (evening dosing) FF/VI 100/25 mcg versus FF 100 mcg (primary objective) and FF/VI 100/25 mcg versus FF/VI 200/25 mcg (descriptive comparison only) in patients (n = 1039) ≥12 …
Authors
Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
Journal
Journal of Asthma, Vol. 52, No. 10, pp. 1073–1083
Publisher
Taylor & Francis
Publication Date
November 26, 2015
DOI
10.3109/02770903.2015.1056350
ISSN
0277-0903
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, InhalationAdolescentAdultAgedAged, 80 and overAndrostadienesAsthmaBenzyl AlcoholsBronchodilator AgentsChildChlorobenzenesDelayed-Action PreparationsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDry Powder InhalersFemaleHumansMaleMiddle AgedRacial GroupsSeverity of Illness IndexYoung Adult